Immunome Stock

Immunome FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Immunome (IMNM) as of Aug 16, 2026 is 94.45 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 56.08 % — a change of 68.41% (higher).

FCF Conversion

94.45 %

YoY

68.41%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Immunome is 2026 94.45 % . FCF Conversion Rate (FCF/EBITDA) of Immunome was 2025 56.08 % . It decreases by 68.41% higher compared to the previous year.
Access this data via the Eulerpool API

Immunome Stock analysis

What does Immunome do? Immunome Inc was founded in 2020 and is based in Pennsylvania, USA. The company specializes in researching and developing therapeutic antibodies and vaccines. Its goal is to develop innovative drugs for the treatment of cancer, infectious diseases, and autoimmune diseases. The history of Immunome Inc began with the founding by a group of scientists and entrepreneurs who combined their expertise and experience in the field of immunology and biotechnology. Their goal was to build a company capable of conducting groundbreaking research and developing new therapies that offer improved chances of recovery. The business model is based on the discovery and development of monoclonal antibodies that have high specificity and effectiveness against specific target molecules. The strategy is to focus on new approaches to identify target molecules in order to develop drugs that specifically target the causes of diseases. Immunome Inc specializes in various areas: cancer, infectious diseases, and autoimmune diseases. Within these areas, the company focuses on identifying target molecules and developing monoclonal antibodies and vaccines that act specifically against these molecules. Products offered by Immunome Inc include monoclonal antibodies against various types of cancer such as breast cancer, prostate cancer, and lung cancer. These antibodies are currently being tested in clinical trials and show promising results. The company also offers a range of vaccines against various infectious diseases, including adaptable influenza vaccines and vaccines against the Ebola virus. In addition, Immunome Inc places great importance on the development of therapies for autoimmune diseases. This includes, for example, the discovery of autoantibodies that selectively balance the immune system and thus can control autoimmune diseases. In summary, Immunome Inc is an innovative biotech company specializing in the development and commercialization of monoclonal antibodies and vaccines against cancer, infectious diseases, and autoimmune diseases. Through its groundbreaking research, the company has the potential to save lives and contribute to the cure of diseases. Immunome is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immunome stock

FCF Conversion Rate (FCF/EBITDA) of Immunome is 94.45 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Immunome changed from 56.08 % to 94.45 %, representing a 68.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Immunome since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Immunome with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Immunome

All Key Metrics — Immunome